[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Semmelweis University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":735},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,47,77,103,133,162,190,215,245,274,302,338,361,392,418,445,466,500,549,569,595,632,666,687,713],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100054152","inhibition-of-myopia-progression-with-optical-devices-100054152",false,"NCT07698977","Inhibition of Myopia Progression With Optical Devices","Inclusion Criteria:\n\n* • Participants must be between 6 and 15 years of age at the start of myopia progression treatment\n\n  * Caucasian ethnicity\n  * Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph\n  * Wearing myopia-control glasses while awake\n  * Participation in follow-up examinations every 6 months\n\nExclusion Criteria:\n\n* • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)\n\n  * Premature birth before the 32nd week of gestation\n  * Previous eye-opening surgery (e.g., lens removal)\n  * Traumatic eye injury\n  * Known connective tissue disorder (e.g., Marfan syndrome)\n  * Irregular or improper use of progressive-lens glasses\n  * Failure to attend the follow-up examinations scheduled every 6 months","ALL","6 Years","15 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","This observational study aims to determine whether optical devices designed to slow myopia progression and\u002For environmental factors can prevent myopia progression in the pediatric and adolescent myopic population.\n\nThe study aims to answer the following questions:\n\n1. How does myopia progression change with age while wearing myopia progression control glasses?\n2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?\n3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? This will be a self-controlled observational study. Participants who are myopic after cycloplegic refraction will be prescribed DIMS glasses. DIMS stands for \"defocus incorporated multiple segments,\" a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children.\n\nPatients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time.\n\nPatients will visit the clinic once every six months for checkups and the following tests:\n\n* Best corrected visual acuity test\n* Stereopsis\n* Automatic refractometry\n* Bulbar axial length measurement\n\nIn a follow-up study, researchers will compare myopia progression with environmental and baseline factors to learn about the long-term effects of DIMS lenses on myopia progression.",[25,26,27],"Myopia Progression","Myopia","Myopia, Child Myopia Progression",[29,30,31,32,33],"myopia","myopia progression","optical device","DIMS lenses","bulbar axial length","RECRUITING","2026-07-07",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2026-06-02",{"date":42,"type":21},"2027-05-31",{"name":44,"class":45},"Semmelweis University","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100611262","prophylactic-sphincterotomy-in-acute-biliary-pancreatitis-patients-unfit-for-surgery-100611262","NCT07238296","Prophylactic Sphincterotomy in Acute Biliary Pancreatitis Patients Unfit for Surgery","Prophylactic Endoscopic Sphincterotomy in Patients Unfit for Cholecystectomy After an Acute Biliary Pancreatitis Episode - an Open-label, Two-armed, Randomized Controlled Trial","PROSECCO","Inclusion Criteria:\n\n1. adult patients (above 18 years)\n2. naïve papilla\n3. evidence of AP based on the Atlanta criteria:\n\n   * pain in the upper abdomen\n   * serum amylase or lipase concentration \\> 3 times the upper limit of normal\n   * imaging features of acute pancreatitis on abdominal imaging\n4. high probability of a biliary etiology:\n\n   * gallstones or biliary sludge on imaging (any type)\n   * dilated common bile duct on imaging defined as \\> 8 mm in patients ≤ 75 years or \\> 10 mm in patients \\> 75 years\n   * abnormal liver enzymes (alanine aminotransferase \\[ALT\\] two times the upper limit of normal)\n5. patients unfit for surgery due to the attending physician's decision e.g. American Society of Anesthesiologists (ASA) class ≥ III; severe heart failure with reduced ejection fraction \\\u003C40%, severe uncontrolled hypertension, chronic kidney disease stage four or five\n\nExclusion Criteria:\n\n1. previous cholecystectomy\n2. previous endoscopic sphincterotomy or pancreatobiliary stenting\n3. ERCP\u002FES is recommended by the guidelines (3)\n\n   * sign of cholangitis\n   * presence of CBD stone on any imaging\n   * signs of stone in endoscopic ultrasonography or magnetic resonance imaging in case of abnormal liver enzymes (persistently elevated ALT and aspartate aminotransferase (AST) with less than a 20% decrease over four days) or dilated CBD (defined as above)\n4. chronic pancreatitis\n5. estimated life expectancy \\\u003C 12 months\n6. ERCP is contraindicated, e.g. the procedure cannot be carried out safely due to the patient's comorbidities or physical status; high risk of bleeding or contraindication of the discontinuation of the anticoagulation therapy.\n7. ERCP is technically not feasible due to altered anatomy, e.g., total gastrectomy, Roux-en-Y gastric bypass anatomy\n8. pancreatobiliary malignancy","18 Years",{"count":57,"type":21},92,"INTERVENTIONAL",[60],"NA","This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of prophylactic endoscopic sphincterotomy (ES) in frail patients unfit for cholecystectomy following an episode of acute biliary pancreatitis (ABP).\n\nEligible patients will be randomized in a 1:1 ratio to either prophylactic ES during the index admission or conservative treatment. The primary endpoint is the time from randomization to the first occurrence of a recurrent pancreatobiliary event within 12 months, including recurrent ABP, cholangitis, choledocholithiasis requiring endoscopic retrograde cholangiopancreatography (ERCP), or cholangiogenic liver abscess. Secondary outcomes include mortality, pancreatobiliary events requiring intensive care unit admission, post-ERCP complications, cholecystitis, and length of hospitalization.\n\nA total of 92 patients will be enrolled. The trial will be led by the Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary, and conducted in accordance with Good Clinical Practice.",[63],"Acute Biliary Pancreatitis",[65,66,67],"ERCP","prophylactic sphincterotomy","cholecystectomy","NOT_YET_RECRUITING","2026-04-27",{"date":71,"type":38},"2026-05-01",{"date":73,"type":21},"2026-07-01",{"date":75,"type":21},"2028-07-01",{"name":44,"class":45},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":55,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":58,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100575141","comparison-of-mist-with-prf-and-gbt-with-prf-in-the-treatment-of-intrabony-periodontal-defect-a-prospective-rct-100575141","NCT06768424","Comparison of MIST With PRF and GBT With PRF in the Treatment of Intrabony Periodontal Defect. A Prospective RCT","Comparison of Minimally Invasive Surgical Therapy in Combination With Platelet Rich Fibrine and Guided Biofilm Therapy Combined With Platelet Rich Fibrine in the Treatment of Solitaire Intrabony Periodontal Defect A Prospective RCT.","Inclusion Criteria:\n\n* solitaire intrabony periodontal defect at least 4 mm\n\nExclusion Criteria:\n\n* Periodontitis with intrabony defect (Intrabony component ≥ 4mm, defect radiological angulation \\> 25°,\n* The patient is able to comply with the study -related procedures (i.e. good level of oral hygiene, follow-up procedures).\n* Patients must not be heavy smokers (\\\u003C5 cigarettes\u002Fday).\n* furcation involvement\n* Full mouth plaque and bleeding scores (FMPS and FMBS) of \\\u003C15% (O'Leary et al. 1972).\n* The patient is able to fully understand the nature of the study, signed informed consent.",true,"65 Years",{"count":87,"type":21},36,[60],"The aim is to evaluate in a prospective, randomized, controlled clinical study the healing of a MIST procedure combined with PRF, or GBT combined with PRF. Clinical, radiological evaluation of the regenerative surgical method and the GBT non-surgical therapy in solitaire deep intrabony periodontal defect.",[91],"Intrabony Periodontal Defect",[93,94],"Guided biofilm terapy","Platelet Rich Fibrine","2026-04-25",{"date":97,"type":38},"2026-04-28",{"date":99,"type":38},"2023-12-20",{"date":101,"type":21},"2027-12-20",{"name":44,"class":45},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100570957","semmelweis-esophageal-cancer-study-noninvasive-prognostic-parameters-in-patients-with-oesophageal-and-esophagogastric-junction-cancer-100570957","NCT06713993","Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer","Noninvasive Testing Procedures, Role of Biomarkers and Anticancer Treatments in Esophageal and Esophagogastric Cancer Survival and Quality of Life of Patients With Cancer of the Esophageopharyngeal and Oesophageophageophageal Junction","Inclusion Criteria:\n\n* Age over 18 years\n* Diagnosis of new-onset esophageal, esophagogastric junction tumor\n* Elective curative surgery (open\u002Flaparoscopic regardless of surgical technique)\n* Patients who have not yet received oncological treatment for their present disease\n\nExclusion Criteria:\n\n* Lack of consent\n* Lack of cooperation\n* Contraindications for some studies: If MR scan is contraindicated, cardiac MR scan is not performed",{"count":111,"type":21},100,"5 Years","The objective of this observational study was to gain a deeper understanding of the epidemiology of the disease in Hungary through a broad analysis of patients with new-onset esophageal-oesophageal-stomach junction tumors, and to identify key parameters that could potentially influence the outcome of the disease and are closely correlated with morbidity and mortality. The investigators' primary objective is to identify potential factors and conditions that could be influenced and modified to enhance the disease outcome.\n\nMain questions:\n\n1. What are the measurable changes in performance, workload, nutritional status, cardiac function, mental status in the patients studied?\n2. What is the time course of the changes during and after treatment?\n3. Which pathological parameters are associated with disease outcome and which are potential points of intervention to improve the course of the disease?\n\nPatients will undergo a detailed physical and nutritional assessment, non-invasive imaging tests and several questionnaires in addition to the usual pre- and post-operative examinations.",[115],"Esophageal Cancer (EsC)",[117,118,119,120,121,122,123,124],"Esophageal cancer","heart failure","sarcopenia","malnutrition","frailty","heart function","Esophageal cancer surgery","cardiovascular abnormalities","2026-04-23",{"date":127,"type":38},"2026-04-24",{"date":129,"type":38},"2024-09-10",{"date":131,"type":21},"2034-09-10",{"name":44,"class":45},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":58,"phases":143,"briefSummary":145,"conditions":146,"keywords":151,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100503542","phase-4-hydrocortisone-therapy-optimization-during-hypothermia-treatment-in-asphyxiated-neonates-100503542","NCT05836610","Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates","Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates - a Pharmacokinetic Study","UniCort","Inclusion Criteria:\n\n* gestational age ≥ 36 weeks\n* provision of whole-body hypothermia treatment (as described by Azzopardi et al.)\n* presence of systemic hypotension (defined as a mean arterial pressure less than the gestational age in weeks)\n* indication for hydrocortisone treatment during hypothermia by the attending physician\n* indwelling arterial catheter to take blood samples without additional painful punctures: umbilical arterial catheter or peripheral arterial catheter\n* written informed parental consent\n\nExclusion Criteria:\n\n* infants who are expected to be \\> 6 hours of age (not suitable for cooling)\n* critical congenital abnormalities\n* genetic disease\n* signed informed consent is unavailable","72 Hours",{"count":20,"type":21},[144],"PHASE4","This is a prospective, single center, pharmacokinetic study of intravenous hydrocortisone therapy for systemic low blood pressure during hypothermia treatment in asphyxiated newborns. Patients will be allocated to hydrocortisone supplementation while receiving conventional inotropic therapy as needed.\n\nThe hypothesis is that a detailed study of hydrocortisone pharmacokinetics during therapeutic hypothermia would help to personalize steroid supplementation in asphyxiated neonates. As the overall metabolic rate decreases with lower body temperature, drug metabolism is likely to be reduced as well, and lower doses, or less frequent dosing will be sufficient to achieve the targeted steroid range and biological effects in asphyxiated neonates with relative adrenal insufficiency. Thus, the investigators are planning to measure initial, baseline serum cortisol levels and serial serum cortisol levels after hydrocortisone supplementation in cooled asphyxiated neonates.",[147,148,149,150],"Hypoxic-Ischemic Encephalopathy","Asphyxia","Hypotension","Circulatory Failure Neonatal",[152,153,154,155,147,148],"Hypothermia treatment","Relative adrenal insufficiency","Hydrocortisone supplementation","Hydrocortisone pharmacokinetics",{"date":97,"type":38},{"date":158,"type":38},"2021-09-21",{"date":160,"type":21},"2027-09",{"name":44,"class":45},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":16,"minAge":170,"maxAge":55,"enrollmentInfo":171,"targetDuration":4,"studyType":58,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":46},"100526293","vr-based-simulation-in-the-preparation-of-children-for-mri---mrvr-100526293","NCT06132854","VR Based Simulation in the Preparation of Children for MRI - MRVR","Efficacy of Virtual Reality Based Simulation in the Preparation of Children for Magnetic Resonance Imaging Examinations: a Randomized Clinical Trial (MRVR)","MRVR","Inclusion Criteria:\n\n1. Informed assent and parental informed consent to participate in the study.\n2. Stated willingness to participate in the intervention and to complete study questionnaires.\n3. Inpatient or outpatient at the Pediatric Center.\n4. Age 4-18 years\n5. Scheduled for MRI examination under anesthesia at the Semmelweis University.\n6. Fluent in Hungarian language\n\nExclusion Criteria:\n\n1. Severe visual impairment or hearing loss that would hinder the participation of the VR and booklet experience.\n2. In case of epilepsy, if the treating physician recommend against participation.\n3. Children with severe intellectual disability which would hinder participation in the VR group e.g. not able to follow simple instructions.\n4. Inpatients, if the treating physician indicates that the child is too unwell for the study.\n5. Face or cranial deformities, wounds on the face and head which would hinder wearing the VR headset.","4 Years",{"count":172,"type":21},288,[60],"The goal of this randomized controlled trial is to evaluate whether a virtual reality based preparation method can efficiently decrease the proportion of children requiring general anesthesia during MRI examinations.\n\nParticipants will take part in a virtual reality environment resembling an MRI before their scheduled MRI examination.\n\nResearchers will compare these children to usual care and a booklet based preparation method to see if less children need anesthesia for completing the MRI examination.",[176,177],"Children, Only","Anesthesia",[179,180,181,182],"MRI","Pediatrics","anesthesia","virtual reality","2026-04-22",{"date":97,"type":38},{"date":186,"type":38},"2023-11-07",{"date":188,"type":21},"2026-12-31",{"name":44,"class":45},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":46},"100569023","patient-specific-implants-psis-for-the-decompression-of-odontogenic-cysts-100569023","NCT06688851","Patient Specific Implants (PSIs) for the Decompression of Odontogenic Cysts","Patient Specific Implants for the Decompression of Odontogenic Cysts","Inclusion Criteria:\n\n-Patients of the Department of Public Dental Health, Semmelweis University, presenting with odontogenic cysts of the jaws that involve anatomical landmarks are included in the study.\n\nExclusion Criteria:\n\n* Patients who have uncontrolled major systemic diseases as classified by the American Society of Anesthesiologists (ASA grades III-IV)\n* Cancer of the oral cavity\n* History of irradiation therapy in the head and neck region within the previous five years,\n* History of uncontrolled psychiatric disorders,\n* Unwillingness to return for follow-up appointments.\n* Patients on medications interfering with bone metabolism, including steroid therapy and antiresorptive medication",{"count":198,"type":21},20,"This study aims to assess the feasibility of the decompression of odontogenic cysts using Patient Specific Implants anchored subperiosteally using osteosynthesis screws.",[201,202],"Odontogenic Cysts","Odontogenic Keratocyst",[204,205,206,207],"cyst decompression","enucleation","customized implant","Patient Specific Implat (PSI)","2026-04-21",{"date":127,"type":38},{"date":211,"type":38},"2024-11-26",{"date":213,"type":21},"2028-01",{"name":44,"class":45},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":58,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":46},"100557075","the-application-of-a-biphasic-calcium-sulfate-graft-material-in-sinus-floor-elevation-100557075","NCT06533397","The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation","Inclusion Criteria:\n\n* Patients over the age of 18 years,\n* Patients who need dental implant-borne prostheses,\n* Patients with insufficient bone height in the posterior maxilla due to sinus pneumatization.\n\nExclusion criteria:\n\n.• Patients who had major systemic diseases as classified by the American Society of Anesthesiologists (ASA grades III-IV),\n\n* psychiatric contraindications,\n* patients on medication interfering with bone metabolism, including steroid therapy and antiresorptive medication,\n* radiation to the head or neck region within the previous five years,\n* localized periapical disease, odontogenic and nonodontogenic cysts, and maxillary sinusitis,\n* evidence of uncontrolled periodontal disease,\n* Alcohol Use Disorder defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5),\n* recreational drug abuse,\n* heavy smoking (\\>10 cigarettes\u002Fday),\n* diseases of the oral mucosa, including blisters and ulcers, i.e.: red and white lesions, pigmented lesions, benign tumors of the oral cavity, and oral cancer. Leukoplakia, Erythroplakia, Precancerous lesions, Oral squamous cell carcinoma and malign tumors of the soft and hard tissues, Oral candidiasis, Oral lichen planus, Psoriasis, Pemphigus, and Pemphigoid.\n* pregnancy or nursing,\n* poor oral hygiene",{"count":222,"type":21},40,[60],"Pneumatization of the maxillary sinus may lead to insufficient bone volume for dental implant placement in the edentulous posterior maxilla. Sinus floor elevation (SFE) surgery with the lateral window technique is a safe and predictable surgical intervention to restore bone height in the maxillary premolar and molar areas. According to the literature, several bone graft materials may be successfully applied for SFE surgery. There is a lack of evidence regarding the application of biphasic calcium sulfate (BCS) for SFE. The healing period following staged SFE is 2-9 months.\n\nThe aim of this study is:\n\n* to evaluate the success of SFE surgery using BCS as graft material,\n* to compare the microarchitecture of the augmented bone depending on the healing period,\n* to evaluate the success of dental implants placed in the augmented bone and that of the prostheses delivered on the dental implants.",[226,227],"Alveolar Bone Loss","Edentulism Nos",[229,230,231,232,233,234,235,236,237,238],"bone graft material","biphasic calcium sulfate","sinus floor elevation","sinus lift","maxillary sinus augmentation","microcomputed tomography","cone beam computed tomography","histology","histomorphometry","dental implant",{"date":127,"type":38},{"date":241,"type":38},"2024-08-24",{"date":243,"type":21},"2031-09",{"name":44,"class":45},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":16,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":58,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":273},"100630204","phase-4-a-study-to-compare-the-efficacy-and-safety-of-extended-and-intermittent-infusion-of-beta-lactams-in-critically-ill-paediatric-patients-100630204","NCT07484633","A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","A Protocol of a Randomised, Two-arm Superiority Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","PEBBLE","Inclusion Criteria:\n\n* paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination;\n* who are receiving β-lactams including meropenem, piperacillin\u002Ftazobactam, cefepime and ceftriaxone;\n* who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration;\n* written consent of the parent or guardian is obtained.\n\nExclusion Criteria:\n\n* palliative care patients;\n* patients participating in other drug trials;\n* patients with impaired renal function if dosing modification is required (estimated Glomerular Filtration Rate \\[eGFR\\]\\\u003C50 mL\u002Fmin\u002F1.73m2 for meropenem, cefepime, and piperacillin\u002Ftazobactam; eGFR\\\u003C10 mL\u002Fmin\u002F1.73m2 for ceftriaxone);\n* patients undergoing plasmapheresis (TPE);\n* patients undergoing extracorporeal therapy (continuous kidney replacement therapy \\[CKRT\\] or extracorporeal membrane oxygenation \\[ECMO\\]);\n* β-lactam allergy;\n* patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours;\n* pregnancy.","0 Hours","17 Years",{"count":256,"type":21},110,[144],"The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.\n\nThe main question it aims to answer is:\n\nIs the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.\n\nParticipants will:\n\n* be given the required antibiotic drug in a 3-hour-long or in a 0.5 hour-long infusion.\n* be examined to make sure their blood drug levels are correct. This will require two blood tests.\n* be treated according to routine care and have examinations and blood tests performed.",[260,261,262,263,264],"Infection","Sepsis","NICU","PICU","Beta Lactams","2026-04-07",{"date":267,"type":38},"2026-04-13",{"date":269,"type":21},"2026-04",{"date":271,"type":21},"2028-04",{"name":44,"class":45},2,{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":58,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":273},"100632093","scvo2-centered-optimisation-of-red-blood-cell-transfusions-100632093","NCT07509203","ScvO2-Centered Optimisation of RED Blood Cell Transfusions","ScvO2-Centered Optimisation of RED Blood Cell Transfusions (SCORED) - Protocol for a Multicenter, Randomised, Controlled Clinical Trial to Compare the Central Venous Saturation (ScvO2) Guided Transfusion Trigger Versus Transfusion Based on Clinician's Decision in the Critically Ill","SCORED","Inclusion Criteria:\n\n* Patient in medical\u002Fsurgical\u002Ftrauma ICU\n* Hemoglobin level between 7g\u002Fdl and 9g\u002Fdl\n* Written informed consent by patient or next of kin\n* Hemodynamically stable:\n\n  * CRT normal\n  * Serum lactate \\\u003C2 mmol\u002Fl\n  * MAP \\>65 mmHg\n  * noradrenalin \\\u003C 0,2 mcg\u002Fkg\u002Fmin and no increase in 6 hours\n  * No new ischemic change on ECG\n* Monitored with CVC, arterial catheter, hourly urine output\n* Respiratorily stable\n\n  * No support or\n  * Nasal canula\u002Fface mask O2 supplementation or\n  * NIV or\n  * Invasive mechanical ventillation: PC\u002FVC\u002FPS, PEEP\\\u003C 15 cmH2O FiO2 \\\u003C 50% and no increase in 6 hours\n* PiCCO or expert ECHO available within 48hours\n\nExclusion Criteria:\n\n* ScvO2\\>80%\n* Acid-base imbalance (pH\\\u003C7.3 or pH\\>7.5)\n* Chronic kidney disease (KDIGO Stage 3-4-5)\n* Acute heart failure (ESC 2021 definition)\n* Pregnancy\n* Active bleeding\n* Neurotrauma requiring intracranial pressure monitoring\n* Morbid obesity BMI \\>40\n* Horowitz Quotient (paO2\u002FFiO2) \\\u003C 200\n* Acute and chronic liver failure (Child-Pugh B,C)\n* Fever",{"count":283,"type":21},600,[60],"This clinical trial aims to personalise red blood cell transfusion strategies in the crtitically ill patients. The amount of transfusions needs to be minimised in order to prevent adverse events and organ dysfunctions linked to high amounts of red blood cell transfusions.\n\nThe researchers aim to investigate the efficacy and safety of measuring the central venous oxygen saturation (ScvO2) (oxygen content in a venous blood sample taken from a central line) to guide clinicians if transfusion is necessary.\n\nThe researchers aim to compare the ScvO2 guided transfusion strategy with transfusion based on the clinician's judgment (taking into consideration the patients' comorbidities and actual vital parameters).",[287],"Anaemia",[289,290,291,292,293],"central venous saturation","transfusion","critically ill","ICU","red blood cell","2026-03-28",{"date":296,"type":38},"2026-04-03",{"date":298,"type":21},"2026-04-15",{"date":300,"type":21},"2029-04",{"name":44,"class":45},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":58,"phases":311,"briefSummary":312,"conditions":313,"keywords":321,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":273},"100629437","comparing-the-effectiveness-of-online-vs-face-to-face-physiotherapy-for-treating-temporomandibular-disorders-100629437","NCT07474662","Comparing the Effectiveness of Online vs. Face-to-face Physiotherapy for Treating Temporomandibular Disorders","Comparing the Effectiveness of Online vs. One-on-one vs. Group Physiotherapy for Treating Myogenic Temporomandibular Disorders: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with myalgia\n\nExclusion Criteria:\n\n* Children, patients with systemic rheumatic diseases (RA, SLE..), previous jaw surgery or trauma",{"count":310,"type":21},90,[60],"Dentists and physiotherapists have two options for treating these conditions: splint therapy and physiotherapy. Right now, the gold standard is individual physiotherapy, which contains manual therapy and active exercises too. Since not many dentists and physiotherapists are experts in this area, patients have to wait for months or even years to get their treatment. Thanks to social media, patients can find many information about their condition while they are waiting, but it's our responsibility to provide safe and effective information. In view of this situation, our aim is to find out if online or group physiotherapy is as effective as individual physiotherapy.",[314,315,316,317,318,319,320],"Temporomandibular Disorders (TMD)","Orofacial Pain","Temporo-mandibular Dysfunction","Temporomandibular Joint and Muscle Disorder","TMD\u002FOrofacial Pain","Temporomandibular Disorder (TMD)","Temporomandibular Disorders (TMDs)",[320,322,323,324,325,326,327,328,329],"Physiotherapy","Manual therapy","Online","Group physiotherapy","Individual physiotherapy","Video exercises","Telemedicine","Teledentistry","2026-03-11",{"date":332,"type":38},"2026-03-16",{"date":334,"type":21},"2026-03-01",{"date":336,"type":21},"2026-07-31",{"name":44,"class":45},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":58,"phases":346,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":46},"100623147","investigation-of-the-effectiveness-of-prophylactic-npwt-cinpwt-in-high-risk-diabetic-patients-with-acute-laparotomy-wounds-100623147","NCT07392853","Investigation of the Effectiveness of Prophylactic NPWT (ciNPWT) in High-risk Diabetic Patients With Acute Laparotomy Wounds","Investigation of the Effectiveness of Prophylactic NPWT (ciNPWT) in High-risk Diabetic Patients With Acute Laparotomy Wounds - A Randomized, Prospective Clinical Trial","Inclusion Criteria:a (all criteria must apply simultaneously):\n\n* Age ≥18 years,\n* Undergoing urgent abdominal surgery,\n* Diagnosis of diabetes mellitus either already present or newly diagnosed at admission\n* High SSI risk. We consider a patient to be at high SSI risk if the operating surgeon categorizes the patient as high risk, and the patient is classified in the III-IV cleanliness category with an open abdominal surgical procedure (laparotomy). \"High SSI risk\" may also be assessed individually based on existing severe risk factors or using an SSI risk calculator (patients with a normal laparotomy SSI risk more than 3 times the baseline are eligible).\n\nExclusion Criteria: (any of the following):\n\n* Pregnancy,\n* Disseminated cancer (irresectable distant metastasis, peritoneal carcinomatosis),\n* Life expectancy of less than 30 days,\n* Refusal to participate in the study.",{"count":256,"type":21},[60],"The aim of this study is to evaluate the effectiveness of prophylactic Negative Pressure Wound Therapy (NPWT) in patients with diabetes mellitus undergoing laparotomy who are at high risk for Surgical Site Infections (SSI). In addition to clinical efficacy, the investigators also plan a cost effectiveness analysis to assess the applicability of this relatively high-cost intervention in a domestic healthcare setting.",[349],"Diabetes (Insulin-requiring, Type 1 or Type 2)",[351,352],"abdominal surgery, SSI, diabetes, emergency surgery","ciNPWT","2026-01-30",{"date":355,"type":38},"2026-02-06",{"date":357,"type":21},"2026-02-22",{"date":359,"type":21},"2026-03-22",{"name":44,"class":45},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":84,"sex":16,"minAge":368,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":372,"conditions":373,"keywords":376,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":46},"100605000","adaptation-of-pediatric-speech-audiometry-tests-into-other-languages-100605000","NCT07156825","Adaptation of Pediatric Speech Audiometry Tests Into Other Languages","Methodological Guide for the Adaptation of Pediatric Speech Audiometry Tests Into Other Languages","Inclusion Criteria:\n\n* Age: limits for age groups: 2-4,5; 4,5-5,5; 5,5-7, respectively.\n* For control goups: normal hearing verified by pure tone audiometry and tympanometry\n* For hearing-impairment groups: stable sensorineural hearing loss confirmed by audiological diagnostics\n\nExclusion Criteria:\n\n* Children presenting with symptoms of upper respiratory tract infections\n* Known speech-language developmental disorders\n* Cognitive disorders","2 Years","7 Years",{"count":371,"type":21},120,"The objective of this study was to offer a comprehensive framework for the adaptation of speech audiometric tests into other languages. To date, this is the first universal protocol of its kind that systematically considers linguistic, phonological, and audiological aspects.\n\nThe present paper provides a protocol and an example for adaptation and standardization of the Mainzer Audiometric Test for Children (MATCH) to another language.",[374,375],"Hearing Loss","Screening",[377,378,379,380,381,382,383],"Audiometry, Speech","Speech Perception","Speech Reception Threshold Test","Speech Intelligibility","Speech","Auditory Threshold","Child, Preschool","2026-01-23",{"date":386,"type":38},"2026-01-26",{"date":388,"type":38},"2024-08-05",{"date":390,"type":21},"2026-07",{"name":44,"class":45},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":58,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":273},"100609212","kinetics-of-procalcitonin-to-reduce-unnecessary-antibiotic-use---comparing-procalcitonin-kinetics-guided-and-absolute-procalcitonin-value-guided-antibiotic-initiation-in-reducing-unnecessary-antibiotic-use-in-critically-ill-patients-100609212","NCT07211620","KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use - Comparing Procalcitonin Kinetics-guided and Absolute Procalcitonin Value-guided Antibiotic Initiation in Reducing Unnecessary Antibiotic Use in Critically Ill Patients","KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use (KIPRUN) - Protocol for a Multi-center, Randomized, Superiority Trial to Compare the Efficacy and Safety of Procalcitonin Kinetics-guided and Absolute Procalcitonin Value-guided Antibiotic Initiation in Reducing Unnecessary Antibiotic Therapy in Critically Ill Patients","KIPRUN","Inclusion Criteria:\n\n* Adult (18 years \\\u003C ) non-surgical, surgical, or trauma patients\n* Suspected new-onset infection on admission or during ICU stay\n* The source of infection is known or highly suspected, and source control has been implemented if needed (i.e., removal of an infected device (e.g., central line, endoprosthesis)\n* Two PCT values are available - one on the day of suspicion of infection and one 24±4 hours earlier.\n* Microbiology sampling has to be performed (according to all presumed sources - blood culture -aerobic and anaerobic, lower respiratory tract sample (tracheal aspirate\u002Fbronchoalveolar lavage), urine, etc.).\n* Written informed consent of the patient (or legal guardian if the patient cannot provide consent)\n\nExclusion Criteria:\n\n* Septic shock (hypotension requiring vasopressor therapy to maintain mean blood pressure of 65 mmHg or greater and having a serum lactate level greater than 2 mmol\u002FL after adequate fluid resuscitation)\n* Infections for which long-term antibiotic treatment is strongly recommended (e.g., infective endocarditis, osteoarticular infections, chronic prostatitis, tuberculosis)\n* Infections related to primary surgical intervention and adequate source control cannot be guaranteed (e.g., fecal peritonitis, pancreatic necrosectomy, infective necrotizing fascitis - i.e., Fournier's gangrene),\n* Indisputable infections (e.g., hepatic abscess, empyema)\n* Poor chance of survival (i.e., expected ICU stay less than 24 hours or initial Acute Physiology and Health Evaluation Score II (APACHE II) \\>30)\n* Admissions after cardiopulmonary resuscitation\n* Severe immunosuppression other than steroid use\n* stem-cell transplant recipients\n* solid organ transplant patients\n* HIV infection with a CD4 count of less than 200 cells\u002Fmm3\n* Neutropenia with less than 500 neutrophils\u002Fmm3\n* Patients on ABs within 72 hours before inclusion\n* Patients in pregnancy or breastfeeding. Women of childbearing age will be screened by a urine pregnancy test before inclusion in the study.",{"count":401,"type":21},250,[60],"The study aims to compare the efficacy and safety of an absolute procalcitonin (PCT) value-guided antibiotic initiation protocol and a protocol using the kinetics of PCT (the difference between the actual and the previous day value) in hemodynamically stable critically ill patients with suspected new-onset infection on admission or during ICU stay.\n\nThe main question it aims to answer:\n\n* Can the investigators decrease the number of unnecessary AB therapies using the kinetics of PCT insted of using absolute PCT values?\n* Is it safe to use PCT kinetics together with the clinical picture to guide AB initiation? AB therapy will be initiated according to predefined PCT protocols (Kinetics and Absolute Group). After 72 hours of treatment, an independent multidisciplinary team (infectologist, microbiologist and intensivist) will decide about the necessity of the treatment with all the relevant results in hand.",[260,261],[406,407,408,409],"procalcitonin","bacterial infection","antibiotics","kinetics","2026-01-08",{"date":412,"type":38},"2026-01-09",{"date":414,"type":38},"2025-11-06",{"date":416,"type":21},"2027-12",{"name":44,"class":45},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":58,"phases":427,"briefSummary":428,"conditions":429,"keywords":432,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":442,"leadSponsor":444,"locationsCount":46},"100600967","freeze-dried-bone-allograft-vs-autologous-bone-blocks-in-the-lateral-augmentation-of-the-jaws-100600967","NCT07104370","Freeze-dried Bone Allograft vs Autologous Bone Blocks in the Lateral Augmentation of the Jaws","Comparison of Freeze-dried Bone Allograft and Autogenous Bone Blocks in the Surgical Reconstruction of Horizontally Atrophied Jaws for Implant Placement: Randomized Clinical Trial","Inclusion Criteria:\n\n* over 18 years old\n* require lateral augmentation for implant rehabilitation\n\nExclusion Criteria:\n\n* Smoking\n* Pregnancy\n* Poor oral hygiene\n* Failure to attend follow-up visits\n* Therapeutic-dose irradiation to the head and neck region\n* Local bone tumors, cysts, or inflammatory processes\n* Decompensated systemic diseases contraindicate surgery\n* Use of medications affecting bone metabolism (steroids, antiresorptive medications such as bisphosphonates, RANKL inhibitor antibodies, VEGF antagonists)\n* Psychiatric disorders contraindicate implant rehabilitation",{"count":426,"type":21},30,[60],"After tooth loss, the alveolar ridge undergoes various modeling and remodeling processes, resulting in overall bone resorption. In case of extensive alveolar atrophy, bone volume must be restored before or during implant placement to achieve successful dental rehabilitation and maximize implant survival and success rates. One possible method for reconstructing severe bone resorption is block bone augmentation.\n\nDue to its biological properties, autologous bone is considered the \"gold standard\" among bone graft materials, as it possesses osteoinductive, osteoconductive, and osteogenic properties.\n\nThe advantages of using allografts over autologous bone grafts include reduced postoperative morbidity, decreased surgical time, and the absence of anatomical limitations regarding the amount of bone that can be harvested. The disadvantage of allografts is the loss of viable osteogenic cells and osteoinductive factors during processing.\n\nThe aim of the study is:\n\n* to compare the success of the bone augmentation surgery depending on whether freeze-dried bone allograft blocks or autologous bone blocks are used,\n* compare the microarchitecture of the augmented bone depending on the bone graft material applied,\n* to evaluate the success of dental implants placed in the augmented bone and that of the prostheses delivered on the dental implants.",[430,431],"Edentulous Alveolar Ridge","Edentulous Alveolar Ridge Atrophy",[433,434,435,436,238,437],"autologous bone","retromolar area","bone block","bone augmentation","freeze-dried bone allograft","2025-09-29",{"date":440,"type":38},"2025-10-03",{"date":438,"type":38},{"date":443,"type":21},"2033-09-01",{"name":44,"class":45},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":84,"sex":16,"minAge":453,"maxAge":17,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":46},"100607462","associations-of-autistic-traits-and-feeding-difficulties-100607462","NCT07188870","Associations of Autistic Traits and Feeding Difficulties","Investigating the Prevalence and Associations of Autistic Traits, Feeding Difficulties, and Atypical Sensorimotor Integration in the Hungarian Early Childhood Population.","BAMBI2025","Inclusion Criteria:\n\n* Age between 1.5 and 6 years\n* Diagnostic status:\n* Diagnosed with autism spectrum disorder;\n* Showing signs of ASD without formal diagnosis;\n* Neurotypical development\n* Children and their parents\n* Parental consent to participate in the study\n\nExclusion Criteria:\n\n* Developmental disorders affecting feeding\n* Children living in institutional care separated from parents\n* Medication affecting feeding behavior\n* Malnutrition due to poverty\n* Parents with low educational attainment or severe communication difficulties preventing questionnaire completion","18 Months",{"count":283,"type":21},"The objective is to assess the prevalence of autistic traits and feeding disorders in the general population.",[457],"Autism Spectrum Disorder (ASD)","2025-09-16",{"date":460,"type":38},"2025-09-23",{"date":462,"type":38},"2025-01-10",{"date":464,"type":21},"2027-09-30",{"name":44,"class":45},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":16,"minAge":474,"maxAge":369,"enrollmentInfo":475,"targetDuration":369,"studyType":22,"phases":4,"briefSummary":477,"conditions":478,"keywords":485,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":46},"100603447","speech-of-kids-after-neonatal-encephalopathy-100603447","NCT07136636","Speech of Kids After Neonatal Encephalopathy","Investigating the Prognostic Accuracy of Different Biomarkers for Detection of Developmental Language Disorder in Children With Neonatal Encephalopathy","SANE","Children born between 2017 and 2023 with moderate to severe HIE, treated with therapeutic hypothermia at Semmelweis University Children's Hospital.\n\nInclusion criteria\n\n1. Born at ≥ 35th week of gestation\n2. Attended follow-up examinations at two years of age\n3. Has parental informed consent\n\nExclusion criteria\n\n1. Hearing loss\n2. Multilingual language environment\n3. Congenital abnormalities\n4. Metabolic disease\n5. Sudden unexpected postnatal collapse\n6. Brain injury not caused by HIE\n7. Severe motor impairment defined as a score \\\u003C70 on the psychomotor development index (PDI) at 2 years of age","0 Years",{"count":476,"type":21},93,"The goal of this ambispective cohort study is to reveal the early indicators of delayed language development in children born with hypoxic-ischemic encephalopathy (HIE).\n\nWe will examine the prognostic accuracy of different biomarkers, with a special focus on the ADC values of the corpus callosum.\n\nThe main questions it aims to answer are:\n\n1. To what extent does hypoxic-ischemic encephalopathy (HIE) in infancy affect intellectual development (IQ), receptive and expressive language abilities at different levels of the language system, and memory capacities related to language development?\n2. What is the relationship between early biomarkers of brain injury-such as blood gas levels, lactate, aEEG, and MRI findings (Weeke scoring system, ADC values of the corpus callosum)-and long-term cognitive developmental outcomes?\n3. What is the incidence of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in this high-risk population of infants with HIE?\n4. Is there an association between the Weeke Total Score and long-term language developmental outcomes?\n5. Can restricted diffusion (ADC values) of the splenium of the corpus callosum serve as an early neuroradiological marker of developmental language disorder (DLD)?\n\nOur participants are children born between 2017 and 2023 with moderate to severe HIE, treated with therapeutic hypothermia at Semmelwies University Children's Hospital. During their first days of life, several neonatal measurements were taken (blood gas markers, aEEG etc.), and at day 4-5, they had an MRI scan of their brain. The MRI scans will be reanalyzed, using the Weeke MRI scoring system. These children underwent a neurodevelopmental follow-up at the age of 2 years and currently, they will have another follow-up at the age of 4-7 years.",[479,480,481,482,483,484],"HIE - Hypoxic - Ischemic Encephalopathy","Language Delay","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","Specific Language Impairment","Intellectual Developmental Disorder",[479,486,487,179,488,489,490,491],"delayed language development","neurodevelopment","biomarker","corpus callosum diffusion restriction","IQ","newborn prediction tool","2025-08-14",{"date":494,"type":38},"2025-08-22",{"date":496,"type":38},"2025-04-01",{"date":498,"type":21},"2026-12",{"name":44,"class":45},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":510,"conditions":511,"keywords":537,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":547,"locationsCount":548},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","25 Years",{"count":509,"type":21},300,"Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536],"Kidney Transplant","Familial Hypercholesterolaemia","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Coarctation of Aorta","Bone Marrow Transplant","Cancer (Solid Tumors)","Leukemia","Lymphoma","Lipoprotein(a)","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[538,539,540],"cardiovascular risk","vasculature","children with chronic conditions","2025-08-04",{"date":543,"type":38},"2025-08-08",{"date":496,"type":38},{"date":546,"type":21},"2029-01-31",{"name":44,"class":45},3,{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":85,"enrollmentInfo":556,"targetDuration":4,"studyType":58,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":46},"100596143","subcutaneous-intersectional-short-pulse-stimulation-in-epileptic-patients-100596143","NCT07041619","Subcutaneous Intersectional Short Pulse Stimulation in Epileptic Patients","Changes in Brain Activity as a Function of Scalp and Subcutaneous Electrical Stimulation Parameters in Epileptic Patients","Inclusion Criteria:\n\n* Age between 18-65 years\n* Patients with drug-resistant focal epilepsy who, after non-invasive or invasive EEG monitoring and neuropsychological, epilepsy protocol cranial MRI, or FDG-PET\u002FCT or FDG-PET\u002FMRI and\u002For ictal SPECT, have been declared unfit for resective epilepsy surgery by an interdisciplinary epilepsy team.\n* Diagnosis of focal or idiopathic generalised epilepsy\n* With antiepileptic drugs, 4 or more focal seizures per month, or frequent spike-wave activity on EEG - min 10 sec\u002Fhour.\n* A patient who is fit to care for the wound and whose home environment this in terms of compliance and cleanliness\n\nExclusion Criteria:\n\n* subjects under 18 years old\n* If the patient is suitable for resective surgery or if there are questions about the patient's suitability for resective surgery of autoimmune aetiology\n* Progressive brain lesions on MRI or a serious internal organ disease or coagulopathy considered serious by your doctor\n* Subjects who have an electrical energy transmitting implant implanted in the brain or other organ(s), including pacemakers, intracardiac defibrillators and any device meeting this definition\n* Pregnancy. Pregnancy should be checked by a pregnancy test for all women of childbearing potential\n* Previous traumatic brain and skull injury, stroke are not exclusionary, but in all such cases the examining physician and the Neunos technical support team should be consulted\n* The presence of metal implants is generally considered contraindicated. In all such cases, the investigating physician or the Neunos technical support team should be consulted",{"count":426,"type":21},[60],"A subgaleal electrode-based system combined with the novel intersectional short-pulse (ISP) stimulation was developed to enable non-invasive, high-intensity neuromodulation. ISP consists of ultra-brief, distributed pulses to maximize electric field strength in target areas while minimizing adverse effects on non-target tissues. Early preclinical studies demonstrate its efficacy in disrupting pathological oscillations and reducing seizures in animal models. This study investigates how targeted electrical brain stimulation by ISP stimulation impacts brain activity in epilepsy patients. The research aims to determine if ISP stimulation delivered via electrodes placed outside and under the scalp can safely and effectively reduce seizure frequency and intensity. Participants include epilepsy patients who haven't responded adequately to medication and aren't eligible for surgery. By precisely tuning stimulation parameters and timing stimulation to specific seizure patterns detected by EEG monitoring, the study seeks to optimize this technique for therapeutic use. The goal is to establish safety and feasibility of this minimally invasive stimulation approach, as well as to achieve preliminary efficacy data thorugh the reduction of seizure durations.",[560],"Epilepsy","2025-06-30",{"date":563,"type":38},"2025-07-03",{"date":565,"type":38},"2021-11-15",{"date":567,"type":21},"2027-12-31",{"name":44,"class":45},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":577,"targetDuration":112,"studyType":22,"phases":4,"briefSummary":579,"conditions":580,"keywords":584,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":594},"100594210","prospective-registry-of-patients-undergoing-cardiac-ct-with-naeotom-alpha-pcd-ct-before-tavi-procedure-100594210","NCT07016477","Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure","Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha Photon Counting-detector CT Before Transcatheter Aortic Valve Implantation","Alpha Registry","Inclusion Criteria:\n\n* Clinically indicated TAVI\n* Clinically indicated CT and invasive coronary angiography\n* There are no contraindications to CT angiography.\n* Understanding and signing the consent form\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Chronic renal failure (eGFR \\\u003C30 ml\u002Fm2)\n* Active oncological treatment\n* Any condition for which TAVI is contraindicated and therefore no prior radiological investigation of TAVI is indicated",{"count":578,"type":21},1000,"The clinical and demographic characteristics of patients undergoing transcatheter aortic valve implantation (TAVI) pose unique challenges for coronary computed tomography (CT) imaging, as this patient population is mainly composed of elderly, frail individuals with severe aortic stenosis, multiple comorbidities, high prevalence of heavily calcified coronary artery disease (CAD) and revascularized coronary arteries. Such vulnerable patients could benefit from a more precise assessment and characterization of their CAD with ultra-high resolution (UHR) photon-counting detector (PCD) CT that would potentially avoid the need for pre-implantation invasive coronary angiography (ICA). This international multicenter prospective registry study aims to investigate the feasibility and diagnostic accuracy of PCD-CT in the assessment of CAD in the high-risk population of patients undergoing TAVI, as compared to ICA.",[581,582,583],"Coronary Artery Disease","Aortic Valve Stenosis","Tomography, X-Ray Computed",[585],"photon-counting detector computed tomography","2025-06-04",{"date":588,"type":38},"2025-06-11",{"date":590,"type":38},"2024-06-01",{"date":592,"type":21},"2030-05-30",{"name":44,"class":45},7,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":603,"enrollmentInfo":604,"targetDuration":4,"studyType":58,"phases":606,"briefSummary":608,"conditions":609,"keywords":617,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":46},"100573513","early-phase-1-feasibility-and-safety-of-intranasally-administered-breast-milk-in-hie-100573513","NCT06747260","Feasibility and Safety of Intranasally Administered Breast Milk in HIE","Feasibility and Safety of Intranasal Breast Milk in Hypoxic-ischaemic Encephalopathy","F-NEO-BRIGHT","Inclusion Criteria:\n\n* Moderate or severe hypoxic- ischaemic encephalopathy, receiving therapeutic hypothermia\n* ≥ 35. gestational week\n* \\\u003C 48 hours of life\n* Hypothermia treatment for 72 hours\n* Parental consent form\n\nExclusion Criteria:\n\n* Congenital malformation\n* Concurrent cerebral lesions\n* ECMO therapy\n* Contraindication of lactation\n* Mother unable or unwilling to provide fresh breast milk\n* Postpartum asphyxia","48 Hours",{"count":605,"type":21},10,[607],"EARLY_PHASE1","This is a prospective intervention single center study to evaluate the feasibility and safety of intranasal breast milk in hypoxic-ischaemic encephalopathic neonates receiving therapeutic hypothermia.",[610,611,612,613,614,615,616],"Hypoxic Ischaemic Encephalopathy (HIE)","Hypoxic Ischemic Encephalopathy of Newborn","Neonatal Encephalopathy","Neonatal Hypoxic Ischemic Encephalopathy","Brain Injury","Perinatal Asphyxia","Perinatal Asphyxia , Moderate to Severe HIE",[618,619,620,621,622,623],"Hypoxic-ischaemic encephalopathy","Neonatal encephalopathy","Perinatal asphyxia","Breast milk","Breast milk stem cells","Intranasal breast milk","2025-05-19",{"date":626,"type":38},"2025-05-22",{"date":628,"type":38},"2024-11-22",{"date":630,"type":21},"2030-01-01",{"name":44,"class":45},{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":58,"phases":641,"briefSummary":642,"conditions":643,"keywords":652,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":46},"100567636","myocardial-perfusion-quantification-with-spect-using-multi-pinhole-collimator-compared-to-photon-counting-coronary-cta-100567636","NCT06670768","Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","Myocardial Perfusion Quantification With Single Photon Emission Computed Tomography Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary Computed Tomography Angiography","MY-FUSION","Inclusion Criteria:\n\n* suspected coronary artery disease\n* referred to coronary CTA or SPECT MPI by the patient's physician\n* agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)\n* suitable for informed consent\n\nExclusion Criteria:\n\n* moderate or severe aortic valve stenosis\n* atrial fibrillation\n* pregnancy or breastfeeding\n* history of coronary artery bypass graft implantation\n* history of stent implantation\n* chronic renal failure (eGFR \\\u003C 30 ml\u002Fm2)\n* active oncological treatment\n* congenital heart disease\n* left or right bundle branch block",{"count":20,"type":21},[60],"This prospective study aims to compare functional abnormalities detected using myocardial perfusion SPECT imaging (MPI SPECT) with the extent and severity of anatomical findings on coronary computed tomography angiography (coronary CTA). Additionally, the investigators aim to enhance the diagnostic value of MPI SPECT by quantifying myocardial blood flow and utilizing myocardial flow reserve calculated from dynamic SPECT images.\n\n50 patients with suspected coronary artery disease are anticipated to be enrolled. Pharmacological stress and rest-phase dynamic and static MPI SPECT following an additional coronary CTA scan are to be performed. The obtained multimodality imaging data (functional and anatomical parameters) are planned to be compared and subjected to statistical analysis. The results of this study are expected to improve risk assessment for patients with moderate cardiovascular risk and enhance the diagnostic performance of MPI SPECT.",[581,644,645,646,647,648,649,650,651],"Coronary Computed Tomography Angiography","SPECT","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Myocardial Ischemia","Coronary Disease","Chest Pain",[653,654,655,656,657],"Coronary Artery Disease,","Myocardial Perfusion Imaging","Myocardial Perfusion Imaging Absolute Quantification","Myocardial Flow Reserve","Plaque volume","2025-04-24",{"date":660,"type":38},"2025-04-25",{"date":662,"type":38},"2024-03-06",{"date":664,"type":21},"2026-08-30",{"name":44,"class":45},{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":84,"sex":16,"minAge":673,"maxAge":674,"enrollmentInfo":675,"targetDuration":4,"studyType":58,"phases":676,"briefSummary":677,"conditions":678,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":46},"100547553","novomatrix-in-gingival-recession-coverage-case-series-100547553","NCT06409468","NovoMatrix in Gingival Recession Coverage: Case Series","Safety and Efficacy of NovoMatrix in Gingival Recession Coverage \u002FA Pilot Clinical and Histological Case Series\u002F","Inclusion Criteria:\n\n* Male or female, between 20-70 years of age, who request gingival augmentation or recession coverage.\n* Subjects who are willing to sign an informed consent, participate and return for follow-up visits.\n* Subjects without significant medical history and currently not on medications that might complicate treatment outcomes.\n* Subjects demonstrating good oral hygiene (FMPS, FMBS less than 20%).\n\nExclusion Criteria:\n\n* Subjects who do not meet all the inclusion criteria or who will not cooperate with the protocol schedule.\n* Subjects who received and failed a previously placed autogenous graft.\n* Subjects who have significant untreated periodontal disease, caries, infection or chronic inflammation in the oral cavity within two adjacent tooth positions of the clinical trial area.\n* Subjects who have used nicotine-containing products within 3 weeks prior to surgery.\n* Subjects who are insulin-dependent diabetic or if their Hgb1c levels \\> 6.5%.\n* Subjects who have had a history of malignancy within the past 5 years (except for basal or squamous cell carcinoma of the skin or in situ cervical carcinoma).\n* Subjects who are nursing or pregnant.\n* Subjects who are presently taking medications (except estrogen\u002Fprogesterone therapy) or those who are undergoing treatment that in known to have an effect on bone turnover.\n* Subjects who have diseases that affect bone metabolism (excluding idiopathic osteoporosis).\n* Subjects with a history of an autoimmune disease, documented allergy or multiple allergies to any component of the agents used in this study.\n* Acutely infected mucogingival defect site.","20 Years","70 Years",{"count":198,"type":21},[60],"Twenty patients seeking treatment for gingival recession coverage, ranging from 20-70 years of age with multiple Miller Class I or II buccal gingival recessions (depth≥3 mm, at least 3 adjacent teeth) will be recruited for this study. Five patients within the study patient pool looking for further orthodontic or restorative treatment that requires removal of one single rooted tooth within the study site of interest will be selected for histological sample removal. All procedures performed in this study will be executed according to established routine protocols, with the exception of block biopsies of one hopeless tooth per patient (total of 5 patients) at 6 months.",[679],"Gingival Recession, Generalized",{"date":681,"type":38},"2025-04-04",{"date":683,"type":38},"2024-05-05",{"date":685,"type":21},"2025-12-15",{"name":44,"class":45},{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":4,"eligibilityCriteria":693,"healthyVolunteers":84,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":694,"targetDuration":4,"studyType":58,"phases":696,"briefSummary":697,"conditions":698,"keywords":703,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":707,"startDateStruct":708,"completionDateStruct":710,"leadSponsor":712,"locationsCount":46},"100532283","periodontal-plastic-reconstruction-of-soft-tissue-dehiscences-after-the-removal-of-localized-gingival-enlargements-100532283","NCT06210789","Periodontal Plastic Reconstruction of Soft Tissue Dehiscences After the Removal of Localized Gingival Enlargements","Periodontal Plastic Surgical Approaches to Correct Recession and Lack of Keratinized Tissue After Elimination of Localized Gingival Enlargements - a Case Series","Inclusion Criteria:\n\n* patients older than 18 years\n* systematically healthy patients\n* localized gingival enlargement is present that involves maximum 3 teeth\n\nExclusion Criteria:\n\n* pregnant women\n* medication intake that can potentially affect the oral mucosa and its healing\n* heavy smokers (\\>=15)",{"count":695,"type":21},22,[60],"Non-inflammatory recessions and Miller class I-II-III. mucogingival defects after elimination of localized gingival enlargements are frequently encountered challenges in the daily practice. In Miller class II-III. recessions the lack of keratinized tissues often compromise the maintenance a proper oral hygiene, this can cause inflammation, which can result in further periodontal attachment loss. In the literature there are some approaches that aim at widening of keratinized tissues and root coverage at the same time, such as the subperiosteal envelope technique (SET) (Allen 1994) combined with a subepithelial connective tissue graft (SCTG) or a partially epithelialized connective tissue graft (PE-SCTG) (Stimmelmayr 2011). In the eradication of localized gingival enlargement postoperative complications following surgical removal, such as recurrence and subsequent gingival recessions as well as loss of keratinized tissues are commonly observed. Nevertheless, a state of the art comprehensive treatment approach has not been reported yet to overcome the above mentioned sequels. The aim of this study is to present a periodontal plastic surgical approach to definitively eliminate localized gingiva enlargements and to simultaneously correct consecutive Miller class I II-III. recessions, esthetic disturbances. (Ethical committee permission number: SE RKEB: 185\u002F2020.)",[699,700,701,702],"Localized Gingival Enlargement","Epulides","Recurrence","Periodontal; Lesion",[704,705,706,699],"Periodontal reconstructive surgery","Surgical excision","Surgical treatment",{"date":681,"type":38},{"date":709,"type":38},"2024-01-05",{"date":711,"type":21},"2025-12",{"name":44,"class":45},{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":12,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":721,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":723,"conditions":724,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":727,"lastUpdatePostDateStruct":728,"startDateStruct":730,"completionDateStruct":732,"leadSponsor":734,"locationsCount":46},"100583575","patient-blood-management-implementation-in-cee-study-100583575","NCT06878105","Patient Blood Management Implementation in CEE Study","Evaluation of Fixed and Personal Assets for Patient Blood Management Implementation in CEE Countries in Practice","CEEPBM","Inclusion Criteria:\n\n* patients above 18 years of age\n* patients undergoing elective medium and high bleeding risk surgical intervention defined as moderate (\\\u003C500 ml) and high (≥ 500 ml)\n* patient consent\n\nExclusion Criteria:\n\n* no patient consent\n* patients under 18 years of age\n* pregnant patients\n* surgery with a low risk of bleeding\n* the patient underwent emergency (non-elective) surgery",{"count":722,"type":21},2000,"The goal of the study is data collection on available fixed and personal assets required for Patient Blood Management (elements of the 3 pillars of PBM) in Central Eastern Europe countries hospitals, status before and after PBM training.",[725,726],"Anemia","Coagulopathy","2025-03-10",{"date":729,"type":38},"2025-03-14",{"date":731,"type":38},"2024-05-27",{"date":733,"type":21},"2025-12-31",{"name":44,"class":45},""]